The ATC Drug Discovery & Screening (ATC–DDS) fosters multidisciplinary and translational collaborative seed projects between IP research laboratories and the Core Facility PF-CCB to federate all workforces (biologists and chemists) around Drug Discovery & Screening. Through therapeutic development it aims to tackle a large variety of diseases covered by the Institut Pasteur 2019-2023 Strategic Plan: emerging infectious diseases such as Covid-19, antimicrobial resistance (bacteria, fungi, viruses, parasites..), neurological disorders and cancer.
We are happy to invite you to the 2nd Drug Discovery & Screening Symposium “From Bench to Drug Discovery” which will be held on December 7th, 2023 (9am to 4pm) on the Institut Pasteur campus in Auditorium François Jacob.
The symposium is open to all and will follow-up on the Drug Discovery & Screening activities at Institut Pasteur by presentations of research projects with therapeutic impact related to drug development.
Registration is now open !
For obvious safety reasons and limited seatings capacity, registration is free but mandatory (no exception allowed): click here to register !
An ID will be required to access the campus on the day of the event.
Deadline for registration: December 1st, 2023 (7pm)
SCIENTIFIC ORGANIZATION COMMITTEE
Nienke Buddelmeijer, Director of the ATC-DDS & Head of the Cell Shape and Pathogenicity Group – Institut Pasteur, France
Fabrice Agou, Director of the ATC-DDS & Head of the Chemogenomic and Biological Screening Platform – Institut Pasteur, France
CONTACT & INFORMATION
For any question, please contact Emilie Boutet : email@example.com